country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P992353

Copy Link Print Information

ES009

ES009 is a high-affinity LILRB2 antagonist, with IC₅₀ values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

ES009 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG4 kappa

Recommend Isotype Controls

Human IgG4 (S228P) kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[1]

LILRB2

In Vitro

ES009 binds to human LILRB2 overexpressed on EL4-huLILRB2 cells, with an EC₅₀ of 0.49 nM^[1].
ES009 potently blocks the interactions between human LILRB2 and the MHC class I ligands HLA-G and HLA-A2 on EL4-huLILRB2 cells, with IC₅₀ values of 0.16 nM and 0.24 nM, respectively^[1].
ES009 induces a proinflammatory phenotype in human monocyte-derived dendritic cells by blocking LILRB2^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ES009 (15-206 mg/kg; i.v.; single dose) exhibits an excellent safety profile in SD rats, with no detectable off-target toxic effects at doses up to 206 mg/kg and no impact on central nervous system or respiratory function at doses up to 135 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) (male and female)^[1]
Dosage:

15 mg/kg; 45 mg/kg; 100 mg/kg; 135 mg/kg; 206 mg/kg
Administration:

i.v.; single dose
Result:

Showed no ES009-related adverse effects across all tested doses, including no changes in clinical signs, body weight, food consumption, clinical pathology, immunotoxicity, or histopathology.
Detected no effects on central nervous system function or respiratory system function up to 336 hours post-dose.
Determined the maximum tolerated dose to be 206 mg/kg, the highest feasible dose tested.

Gene ID

10288 [NCBI]

Accession

Q8N423

Target

LILRB2/ILT4

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

Anwendung

ELISA, FACS, Functional assay

Chemical Information

Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Niu X, et al. LILRB2 inhibition by blocking antibody ES009 reprograms immunosuppressive myeloid cells and enhances T-cell-mediated tumor immunity. Hum Vaccin Immunother. 2026;22(1):2659499. [Content Brief]

[2]. Ganju V, et al. 596 A first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the LILRB2 inhibitor ES009 in patients with advanced solid tumors[J]. 2025.

[3]. Niu X, et al. 1062 ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation[J]. J Immunother, 2022, 10(2): A1-A1595.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Gene ID
- Accession
- Target
- Conjugated
- Reconsititution
- Format
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ES009

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

ES009 Related Classifications

HY-P992353 Related Classifications